A drug developed by National Taiwan University Hospital (NTUH) has been approved for sale in the European Union for the treatment of aromatic-L-amino acid decarboxylase (AADC) deficiency, a rare life-threatening disorder that affects children, the hospital said Friday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Sports
Taiwan gymnasts win silver, bronze at World Challenge Cup
09/15/2025 10:39 AM - Business
U.S. dollar higher in Taipei trading
09/15/2025 10:11 AM - Society
Taiwan headline news
09/15/2025 10:00 AM - Business
Taiwan shares open higher
09/15/2025 09:08 AM - Politics
Taiwan FM condemns political violence after Charlie Kirk's death
09/14/2025 09:48 PM